Navigation Links
Drugs Delivered Into CNS More Effective In Treating Rheumatoid Arthritis

In a new approach to treating rheumatoid arthritis (RA), researchers found that drugs delivered into the central nervous system worked better in the treatment of rheumatoid arthritis, at least in arthritic rats.// In the research carried out on arthritic rats, the researchers delivered the drug directly into the spinal cord to block the p38 protein, a protein critical to the development of RA. The findings of the research done by Gary Firestein and colleagues from University of California, San Diego have been reported in the international open-access medical journal PLoS Medicine.

Rheumatoid arthritis is a disease marked by chronic inflammation, leading to joint pain and destruction. Pain and inflammation in the joints are constantly monitored by the central nervous system (CNS, i.e. the brain and spinal cord). Scientists have long suspected that the CNS can regulate inflammation and immune responses in the body's "periphery", but little is known about how this works. Firestein and colleagues focused on a protein called p38, which is involved in a number of cellular processes critical to the development of RA. Several substances that block the action of p38 are effective in animal models of arthritis and are currently being tested in clinical trials in patients with RA.

Based on the observation by other scientists that p38 is activated in the CNS in response to peripheral pain, and on Firestein and colleagues' own finding that this is true in response to inflammation as well, the researchers blocked p38 with drugs directly delivered to the spinal cord of the arthritic rats. They found that the treated rats had substantially less inflammation, arthritis, and joint destruction, compared with rats that had undergone the same treatment but received no active drug. Treatment of arthritic rats with the same amount of drugs given directly under the skin (the "systemic treatment" that is currently being tested in RA patients, but with much hi
'"/>




Page: 1 2

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
(Date:7/25/2008)... New program delivers immediate co...[24-hour telephone access to language interpreters...g multilingual solutions. , ...LLE® http://www.lle-inc.com/index.html [(Lan...ider of interpretation, translation, and language ...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
(Date:7/24/2008)...TON-SALEM, N.C. Researchers at Wake Forest Unive...-standing clinical belief that the hepatitis C vir...restore itself after HIV patients are treated with..., Hepatitis C (HCV) infection is more serious in...e, according to the Centers for Disease Control. I...
(Date:7/24/2008)...UTH, Minn., July 24 /PRNewswire-FirstCall/ -- ev3 ... to report its 2008 second quarter and,year-to-dat...second quarter,and year-to-date financial results ...ding hours., The company will host a conference c...m. Eastern Time) on Tuesday, July 29, 2008. ev3,ma...
Breaking Medicine News(10 mins):Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...ors of All India Institute of Medical Sciences (AI...ll //in Lok Sabha on Thursday intensified with fiv...ike - Dr Anil Sharma, spokesman of the AIIMS Resid...the doctors would continue attending duty and serv...
...Ease Dietary Supplement, a product containing the ...ndent on it when used just for few months. // Est...which should be consumed only under a practitioner...r of side effects like loss of memory, confusion, ...
... wish-list of many scientists and sufferers the wo...–child of an //Australian scientist, whose perseve...th of cancer cells, seems to have paid off. Prof...king on his ‘baby’ for the past 20 years, may just...
...mptoms of high fever and bodyache has killed 12 ch...g to official sources, 12 children died in two or ...strict due to the disease commonly referred as 'kh...a dozen children were suffering from the same dise...
Other Medicine News:
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...cology Patient Accrual, DENVER, July 24 /PRNewswi...anization (RMO), has contracted with five leading ...ite management services for their,clinical trials ...The new,trials include the following disease indic...tic Breast Cancer, Metastatic Sarcoma, Chronic Mye...
(Date:7/23/2008)... print edition of Clinical Ch.../- A Roche Diagnostics-sponsored,pilo...e natriuretic peptide,(NT-proBNP) confirms the pot...in predicting the risk of cardiovascular adverse e...al anti-inflammatory drugs of,the COX inhibitor cl...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 1Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 2Origin of cells for connective tissues of skull and face challenged 3415 1Origin of cells for connective tissues of skull and face challenged 3415 2Origin of cells for connective tissues of skull and face challenged 3415 3Journal of Ultrasound In Medicine features bioeffects consensus report 20179 1Graduates Forced to Join Millions of Uninsured Americans 20174 1Graduates Forced to Join Millions of Uninsured Americans 20174 2Graduates Forced to Join Millions of Uninsured Americans 20174 3
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
...-FirstCall/ --,NeurogesX, Inc. announced today the...se 3 trial in postherpetic neuralgia (PHN).,Misha-... University,of Wisconsin in Madison and lead acade...present the results of the study in a,June 8 poste...Neuropathic Pain in Berlin, Germany. Dr. Backonja,...
Other Medicine Technology:Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4
...eeds I-125 are brachytherapy sources which are imp...mors, especially in the prostate. The seeds remain...ic effect, i.e. after radioactive decay is complet...ey are supplied in a sterile form. Isoseeds I-125 ...
...mirrors for complete anterior chamber angle viewin...or easy handling and stability. Choice large or sm...llows static or dynamic gonioscopy without methylc... coating protects mirrors and is compatible with m...
Three mirrors of 64, 67 and 73 and a small diameter contact surface for use without methylcellulose. The fundus can be viewed through the central axis of the lens. Multi-layer polymer coating protect
West lacrimal cannula blunt tip with side port.
Medicine Products: